O le Flagship Pioneering i aso nei na faʻaalia ai le Vesalius Therapeutics, o se kamupani e taulaʻi i le toe faʻamalamalamaina o le malamalama ma togafitiga o faʻamaʻi e mafua ai le 90% o gasegase o tagata. E $75 miliona na muai tuuina atu e le Flagship e lagolago ai le atina'eina o le fausaga a Vesalius ma le paipa muamua o vailaau fou. Christopher Austin, MD, o le sa avea muamua ma Faʻatonu Faʻatonu o le National Center for Advancing Translational Sciences (NCATS) i le National Institutes of Health (NIH), o le a taʻitaʻia le kamupani e avea ma Pule Sili. Dr. Austin na auai i le Flagship ia Mati o le 2021 o le Pule Sili-Paaga.

“O le alualu i luma i le togafitia o nisi o maʻi sili ona mataʻutia o le sosaiete e leʻi gaoioi vave i le mea e mafai ai ona e leʻi faʻamalamalamaina saʻo e le tatou pisinisi le faʻafitauli. I le Flagship, na matou iloa ai o le taulimaina o nei tulaga e manaʻomia ona matou mafaufau ese, "o le tala lea a Doug Cole, MD, Managing Partner i Flagship Pioneering, faʻavae o Vesalius, ma le Taitaifono o lana Komiti Faʻatonu. “Na fa'avae Vesalius e fa'atatau tonu le auala tatou te va'ai ai, su'esu'eina, ma togafitia fa'ama'i masani ia e tele lava ina le amana'ia e le biotechnology. Matou te talitonu o la matou auala o le a i ai se suiga i lo matou gafatia e togafitia ai faʻamaʻi e mafua ai le ivasefulu pasene o mafatiaga ma le oti i le lalolagi."

I le taimi nei, o le tele o fa'ama'i e a'afia ai le faitau miliona o tagata gasegase i le lalolagi atoa e tasi le su'esu'ega (fa'ata'ita'iga, ma'i suka) lea e aofia ai le tele o fa'ama'i 'ese'ese, e a'afia ai vaega 'ese'ese o tagata mama'i ma fa'ama'i eseese. O lenei mea e masani ona iʻu ai i faʻailoga tulaga ese, lea e faʻaosoina e le faʻalavelave i faʻasologa o kenera e ese mai i avetaavale o loʻo maua i isi vaega - o lona uiga o tagata mamaʻi o loʻo faʻasoa i aso nei se faʻamaʻi, o le mea moni, e le o mafatia uma i le maʻi tutusa.

Vesalius' DIAMOND platform e galue e pei o se prism e tu'u'ese'ese ai gasegase i ni vaega fa'apitoa e fa'aoga ai le atamai fa'apitoa ma le a'oa'oina o masini e fa'amalamalamaina ai le biology o lo'o fa'avae ai le fa'aaliga ile falema'i. O le DIAMOND na te faia ni faiga fa'ata'ita'iga fa'apitoa e maua mai i tagata ma'i e fa'aogaina e su'e ma fa'ailoa ai sui o vaila'au e toe fa'afo'i ai nei ta'amilosaga i le ola maloloina. O lenei faiga o le a faʻaalia ai ni auala fou e atiaʻe ai togafitiga mo faʻamaʻi faʻamaʻi muamua.

Fai mai Dr. Austin, "O ma'i masani e le o monolithic, o le mea moni o se fa'aputuga o le tele o fa'ama'i fa'ale-aganu'u ma fa'ama'i fa'apitoa e a'afia ai tagata mama'i. O le matou DIAMOND platform e mafai ai ona matou faʻamalamalamaina nei vaega faʻamalamalamaina o tagata mamaʻi ma malamalama i latou faʻasoa faʻasoa i le fale i luga o le togafitiga saʻo mo le vaega saʻo o gasegase. E ala i le fa'amamaina o vaega o gasegase e ala i a latou fa'ailoga tutusa, genetics, ma le biology, matou te talitonu e mafai ona fa'aleleia le avanoa e manuia ai le atina'eina o vaila'au mo fa'ama'i taatele. E le gata i lea, e ala i le faʻaaogaina o faʻataʻitaʻiga faʻataʻitaʻiga faʻataʻitaʻiga a le tagata, o la matou faʻavae e matuaʻi lelei tele i le suʻeina o togafitiga fou e faʻaleleia atili ai olaga o maʻi.

“Matou te manaʻomia ni manatu tetele ma ni faanaunauga malosi pe afai o le a iʻu ina matou atiaʻe ni vaifofo aogā mo nisi o maʻi sili ona mamafa o sosaiete, ma o le poto masani a Chris i le toeitiiti atoa le sefulu tausaga o le faatonu o le National Center for Advancing Translational Sciences i le NIH e atoatoa. fetaui mo le misiona a Vesalius,” o le tala lea a Noubar Afeyan, Ph.D., Founder ma Pule Sili o le Flagship Pioneering. “O lana va'aiga fa'ata'atia na ta'ita'ia ai le aga'i i luma i le fa'aliliuga fa'asaienisi lea na fa'atelevaveina ai le atina'eina o le tele o vaila'au fa'afouga. E iai foʻi lona poto masani i le suʻesuʻeina o sini e ala i lana galuega ma le National Human Genome Research Institute ma Merck o le fetaui lelei lea mo le isi luʻitau tele i le soifua maloloina.

Ua iloga le alualu i luma o Vesalius i le faailoaina o le kenera i totonu o le to'atele o tagata mama'i i le tele o fa'ama'i faigata ona togafitia, ma maua ai le fa'amaoniga-o-manatu mo lona auala, ma tatala le faitoto'a i le tele o vaega fa'afoma'i eseese. O lo'o fa'amoemoe le kamupani e fa'afaigaluegaina le silia ma le 200 tagata i le isi lua tausaga o lumana'i e lagolago ai le aga'i i luma o ana fa'avae ma polokalame.

OA MEA E AVEA MAI LENEI TUSI:

This often results in unique symptoms, which are driven by abnormalities in genetic circuits that differ from the drivers found in the other groups – meaning that patients who today share a diagnosis are, in fact, not all suffering from the same disease.
Our DIAMOND platform enables us to elucidate these defined groups of patients and understand their shared biology to home in on the right therapeutic for the right group of patients.
He also has deep experience in genetic target discovery through his work with the National Human Genome Research Institute and at Merck that is the perfect match for the next great challenge in healthcare.